Instrumento Inactivo

Otros idiomas Avalanche Biotechnologies Inc Nasdaq

Acciones

US05337G1076

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	15/05
Adverum Biotechnologies: Q1 Earnings Snapshot	09/05
Adverum Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights	09/05
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences	06/05
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences	03/05
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting	25/04
Adverum Biotechnologies Files $200 Million Mixed Shelf	21/03
Adverum Biotechnologies: Q4 Earnings Snapshot	18/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates	18/03
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference	28/02
Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors	21/02
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	12/02
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD	08/02
Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD	08/02
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	05/02
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing	05/02
Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors	05/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Avalanche Biotechnologies Inc Nasdaq

Acciones

US05337G1076

Otros idiomas

Filtros